Dr. Fabian Falkenbach

Head of Prostate Biopsy @uniklinik_hd - clinician scientist @dkfz , boy dad, coffee enthusiast

[Anwar Padhani @ProfPadhani]

There's more than Will Rogers to consider. PSMA-PET depicts a different disease state. @piet_ost There is also asymmetric utility in rule-in and rule-out for randomising (Rx escalation) @IP_London @declangmurphy @DrMHofman only a randomised study like AVIDITY will satisfy all 🙏

[JAMA Oncology @JAMAOnc]

Local salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. https://t.co/3PYHf4AFp4

[Benjamin J. Davies MD, MBA @daviesbj]

My first paper with Alex and it's a doozy (also jay, canes, QDT)

$ISRG and others stealing our IP. We have issues

[NEJM @NEJM]

Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. Full results of the STAMPEDE-1 and PATCH trials: https://t.co/sKJ6Sr6WiW

[Peter Mac Cancer Centre @PeterMacCC]

A clinical trial co-led by Peter Mac has shown a way to reduce the need for invasive biopsies to check for prostate cancer.

It found PSMA PET/CT scanning could halve the number of people requiring a biopsy, without missing any harmful cancers.

More: https://t.co/MXB3n39KC5

[Shankar Siva @_ShankarSiva]

📣@ChapinMD presents best systemic therapy trial +/- prostatectomy n=120 randomised phase II trial in #prostatecancer. No observed benefit for prostatectomy 🔪🩸. Ongoing recruitment for SWOG-1802, pls support this important clinical trial 👏🏽#pcsm #EAU26

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 PORTAL nomogram for PSMA PET–staged oligorecurrent #prostatecancer

@TheLancetOncol

🎯 Predicts ADT-free survival after MDT

🔑 signals:
1⃣↑ pre-MDT PSA
2⃣Short PSA-DT
3⃣3–5 lesions
4⃣M1 disease

📊 2-yr ADT-free survival:
🟢 Low risk: 84%
🟡 Intermediate: 71%
🔴 High risk: 45%

C-index ~0.66 → modest individual prediction, useful group stratification.

⭐️Risk-adapted MDT decision-making just got sharper

🔗https://t.co/4uIn1k0QFB

@urotoday @UrologyTimes @PCFnews

[Matt Cooperberg @dr_coops]

2026 @AmericanCancer Statistics are out. #prostatecancer is now #1 in incidence for all US ppl. Mortality numbers also up though ASR is slightly down; mortality still >2x for Black men.

New USPSTF guidelines expected this year… Get screened!!

https://t.co/7KktgaNbCi

[JAMA Oncology @JAMAOnc]

Cribriform morphology predicted 15-year metastasis in #ProstateCancer, with radiotherapy plus neoadjuvant ADT reducing this risk, while cribriform-negative patients did not benefit from early radical treatment for metastasis prevention. https://t.co/0TDPTwCwm6

[tombal @BertrandTOMBAL]

Ending the Inequality—Why Men with Prostate Cancer and ADT suffer from hot flushes when women have access to effective therapy? When the industry discriminates against male patients. @PblanchardMD, @AnthonyMJoshua, @Silke_Gillessen, @PedraniMartino https://t.co/Aaqicv7tCa

[Ben Van Calster @BenVanCalster]

Our overview of and guidance for performance measures to evaluate medical AI is finally out!

- Stop bashing AUROC
- Calibration + clinical utility are key
- Plot risk distributions
- Classification measures are improper

https://t.co/m3xrAHDzdg

[Andrew Vickers @VickersBiostats]

MRI is a great tool in prostate cancer. The problem is, quality in practice might not be quality we see in studies. Nice study from @dr_coops showing that in the VA, MRI not good enough to rule out biopsy. https://t.co/h7Z6N6T6Fl

[Hashim U. Ahmed @LondonProstate1]

How much cancer is there in a prostate biopsy?

‼️Over a dozen different ways that pathologists can measure this

〽️ Lots of variability

🔀 Differential impact on treatment decisions

Great talk by Prof Glen Kristiansen

@aimhaider @daniel_berney

[Michael Hofman @DrMHofman]

🌙LUNAR phase 2 RCT: adding Lu-177 PSMA to SABR for oligorecurrent prostate cancer significantly improved PFS without increased toxicity

Just out in @JCO_ASCO: https://t.co/3i8RwkJRy3

Impressive trial and results @AmarUKishan @CalaisJeremie and team

[Dr Rishabh Jain @DrRishabhOnco]

🧬 Why Docetaxel Works in Prostate Cancer (and Others Don’t 😮)

Not all taxanes are born equal — one cracked the prostate code 🧩

💥 Docetaxel = The AR Disruptor
•Freezes microtubules → mitotic chaos (G₂/M arrest)
•Phosphorylates Bcl-2 → flips the “self-destruct” switch
🚫 Stops androgen receptor (AR) from entering the nucleus — and that’s its secret weapon!

⚖️ Paclitaxel vs Cabazitaxel: Why They Miss the Mark?

•Paclitaxel → can’t penetrate prostate tumor microenvironment effectively ❌

•Cabazitaxel → beats resistance pumps 💪 but doesn’t block AR trafficking as powerfully

👉 Only docetaxel truly starves the tumor of AR signaling

🧠 Proof in Trials
•mCRPC: OS ↑ in TAX-327
•mHSPC: OS ↑ in CHAARTED & STAMPEDE
•Now the backbone for ARSI + PARPi combos

💡 Takeaway:
Docetaxel isn’t just chemo - it’s a molecular double agent that shuts down both cell division and androgen signaling.

🔖 Save this gem for viva, boards & clinic rounds!
#OncoTwitter #ProstateCancer #MedTwitter @myESMO @esmo_open @OncoAlert @ASCO @Uromigos

[JNM @JournalofNucMed]

Intra- and interrater agreement with the AI platform aPROMISE were substantial to almost perfect, comparable to the standard-of-care image viewing software. https://t.co/HU17fVqonJ

#NuclearMedicine #AI #ProstateCancer @ffmed

[Adam B. Weiner, MD @Adam_Weiner535]

🚨23 years of PSA screening in @NEJM 🚨

👉ERSPC RCT of >162k patients

📅Median 23 year f/u PSA screening lead to...

📉 #prostatecancer mortality by 13%

✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa

📉Risk of advanced PCa by 34%

⭐️Benefit continues to rise over time as harm-benefit ratio improves

🔗https://t.co/hGCAfGpmhE

@PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc

[Matt Cooperberg @dr_coops]

Exciting 23 year update from the ERSPC #prostatecancer screening trial from @MoniqueRoobol and team, and a great editorial @VickersBiostats. NND is down to 12 and still falling! And the benefit:harm ratio would be even better w/ modern screening/dx/tx pathways.

[Eric Topol @EricTopol]

The prostate cancer PSA screening story over 23 years of follow-up for >166,000 participants: more detection, small reduction of mortality @NEJM https://t.co/MWckILe0Ni

[Zach Klaassen @zklaassen_md]

Drug Approvals in 🇺🇸 for Prostate Cancer (2010-2025)

Go ahead and bookmark this beauty from @PBarataMD

@urotoday #ESMO25